Tao Capital Partners

Tracked participation in 2 Atlas companies, with 0 explicitly attributed leads.

2portfolio companies

6round participations

0lead positions

Nov 2025latest activity

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic Therapeutics—Oct 2021 → Nov 20255 roundsParticipant—

CCrusoeNeocloudsCrusoe is a vertically integrated AI infrastructure provider built around energy-first compute. The company says it…$10Bvaluation$3.8BraisedRecent roundsSeries E · Oct 2025$1.4B · led by Mubadala Capital, Valor Equity PartnersDebt financing (credit facility) · Jun 2025$750M · led by Brookfield Asset ManagementDebt financing (credit facility) · Mar 2025$225M · led by Upper90 Capital ManagementCrusoe$1.8BApr 2022 → Apr 20221 roundParticipant—

DateCompanyRoundRaisedValuationRoleEvidence

Nov 10, 2025ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic TherapeuticsOversubscribed financing round (company described as >$100M)$100M—Participant

Source ↗

Jun 18, 2024ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic TherapeuticsSeries B extension (oversubscribed)$50M—Participant

Source ↗

Oct 03, 2023ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic TherapeuticsSeries B (oversubscribed)$100M—Participant

Source ↗

Jun 18, 2023ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic TherapeuticsSeries B Extension$50M—Participant

Source ↗

Apr 21, 2022CCrusoeNeocloudsCrusoe is a vertically integrated AI infrastructure provider built around energy-first compute. The company says it…$10Bvaluation$3.8BraisedRecent roundsSeries E · Oct 2025$1.4B · led by Mubadala Capital, Valor Equity PartnersDebt financing (credit facility) · Jun 2025$750M · led by Brookfield Asset ManagementDebt financing (credit facility) · Mar 2025$225M · led by Upper90 Capital ManagementCrusoeSeries C$350M$1.8BParticipant

Source ↗

Oct 03, 2021ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic TherapeuticsSeries B$100M—Participant

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Source ↗